GRO Biosciences Inc. (GRObio), an emerging biotechnology company, announced the closing of a Series A financing totaling $25 million co-led by Leaps by Bayer and Redmile Group.

The financing was joined by lead seed investors Digitalis Ventures, Innovation Endeavors and others bringing the total investment to $31.2 million.

GRObio's mission is to transform protein-based therapies for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases.